MYL

迈兰实验室
NASDAQ

实时行情|Nasdaq Last Sale

21.15
+0.23
+1.08%
盘后: 20.81 -0.34 -1.61% 17:20 02/21 EST
开盘
20.84
昨收
20.93
最高
21.31
最低
20.68
成交量
493.99万
成交额
--
52周最高
31.75
52周最低
16.63
市值
109.17亿
市盈率(TTM)
202.20
分时
5日
1月
3月
1年
5年

分析师评级

17位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MYL价格均价为25.31,最高价位31.00,最低价为21.00。

EPS

MYL 新闻

更多
  • 3 Best Drugmakers That Are Immune to Coronavirus Fright
  • Zacks · 2天前
  • Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy?
  • Zacks · 3天前
  • FPA Crescent Fund Year-End 2019 Commentary
  • Seeking Alpha - Article · 3天前
  • FDA Approved 1,014 Generic Drugs in 2019
  • MotleyFool.com · 4天前

所属板块

制药
+0.60%
制药与医学研究
+0.54%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

MYL 简况

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Company's Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment primarily develops, manufactures, sells and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream or ointment form. The Europe segment sells pharmaceuticals under their International Nonproprietary Name (INN), such as active pharmaceutical ingredient (API), in certain European countries. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand.
展开

微牛提供Mylan NV(NASDAQ-MYL)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MYL股票新闻,以帮助您做出投资决策。